Development of a kinetic antibody-dependent cellular cytotoxicity assay

J Immunol Methods. 2019 May:468:49-54. doi: 10.1016/j.jim.2019.02.006. Epub 2019 Feb 18.

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) is an important mechanism of action (MOA) of monoclonal antibody (mAb) therapeutics. Target cells opsonized with therapeutic antibody bind and activate FcγR-bearing immune effector cells, resulting in target cell lysis. A key step in mAb drug development is the characterization of ADCC activity for its potential to inform mAb efficacy and safety. A number of in vitro assays are commonly used to assess ADCC. Most are endpoint assays that measure a surrogate marker of cell lysis. Newer imaging technologies allow direct measurement of ADCC-mediated cell lysis over time. In this study, we detail the development and characterization of a kinetic ADCC assay applicable to multiple target and effector cell types. This kinetic assay shows comparable sensitivity to an endpoint fluorescence release ADCC assay, while offering the advantages of a simpler set up and shorter assay time. Our results demonstrate that kinetic ADCC activity is a valid alternative assay format for measuring in vitro ADCC of mAbs.

Keywords: Antibody-dependent cellular cytotoxicity; Cell-based assay; Cellular imaging; Kinetic; Monoclonal antibody.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology*
  • Antibody-Dependent Cell Cytotoxicity / drug effects*
  • Antineoplastic Agents, Immunological / pharmacology*
  • Cell Line, Tumor
  • Flow Cytometry*
  • Fluoresceins / metabolism*
  • Fluorescent Dyes / metabolism*
  • Humans
  • Kinetics
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, B-Cell / immunology
  • Lymphoma, B-Cell / metabolism
  • Lymphoma, B-Cell / pathology
  • Reproducibility of Results
  • Rituximab / pharmacology*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Fluoresceins
  • Fluorescent Dyes
  • calcein AM
  • Rituximab
  • ocrelizumab